๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Shijiazhuang
Clinical trial register · China

Clinical Trials in Shijiazhuang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 28 Guangzhou 28 Fuzhou 22 Chongqing 17 Harbin 14
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing28 Guangzhou28 Fuzhou22 Chongqing17 Harbin14
All 49 locations
Target enrolment
to

Trials with a site in Shijiazhuang

9 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
NCT07619287Myeloid Malignancy
BeOne Medicines
Phase 1
118
Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin
2026-06-23
Recruiting
A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases
NCT07412691Skin Diseases
BeOne Medicines
Phase 1
98
Beijing, Chongqing, Fuzhou, Shijiazhuang, Changsha, Suzhou, Shenyang, Shanghai
2026-03-19
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3
500
Beijing, Fuzhou, Lanzhou, Guangzhou, Jiangmen, Nanning, Guiyang, Shijiazhuang
2025-09-04
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3
630
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-06-11
Recruiting
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT06625593Advanced Solid Tumor
BeOne Medicines
Phase 1
168
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Nanning, Shijiazhuang, Harbin
2024-12-09
Recruiting
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
NCT06598800Advanced Solid Tumor
BeOne Medicines
Phase 1
153
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-10-18
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
BeOne Medicines
Phase 1/2
630
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-07-23
Active, closed
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
NCT05707377Primary Membranous Nephropathy
BeOne Medicines
Phase 2/3
178
Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-04-17
Recruiting
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT04973605Relapsed/Refractory Multiple Myeloma
BeOne Medicines
Phase 1/2
246
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan
2021-09-16
Rows per page Showing 1–9 of 9
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/shijiazhuang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 9 of those studies with a site in Shijiazhuang that also match the filters currently applied.

How many clinical trials are recruiting in Shijiazhuang?

8 of the 9 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shijiazhuang), 9 studies
PhaseStudiesRecruitingShare
Phase 14444.4%
Phase 1/22222.2%
Phase 32222.2%
Phase 2/31011.1%

Most active sponsors

Lead sponsors with the most studies (Shijiazhuang)
Lead sponsorStudiesRecruiting
BeOne Medicines98
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.